Arcus Biosciences (RCUS) Competitors

Arcus Biosciences logo
$16.85 -0.58 (-3.33%)
Closing price 11/16/2026 03:59 PM Eastern
Extended Trading
$16.77 -0.07 (-0.44%)
As of 11/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RCUS vs. PCVX, IBRX, TGTX, SYRE, and MDGL

Should you buy Arcus Biosciences stock or one of its competitors? Arcus Biosciences's main competitors and comparable companies include Vaxcyte (PCVX), ImmunityBio (IBRX), TG Therapeutics (TGTX), Spyre Therapeutics (SYRE), and Madrigal Pharmaceuticals (MDGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Arcus Biosciences compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Arcus Biosciences (NYSE:RCUS) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by company insiders. Comparatively, 7.6% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Arcus Biosciences has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxcyteN/AN/A-$766.63M-$8.06N/A
Arcus Biosciences$247M9.82-$353M-$3.63N/A

Vaxcyte presently has a consensus target price of $110.50, indicating a potential upside of 79.35%. Arcus Biosciences has a consensus target price of $39.36, indicating a potential upside of 133.63%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than Vaxcyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaxcyte
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
Arcus Biosciences
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.69

Vaxcyte has a net margin of 0.00% compared to Arcus Biosciences' net margin of -453.00%. Vaxcyte's return on equity of -42.04% beat Arcus Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
VaxcyteN/A -42.04% -36.82%
Arcus Biosciences -453.00%-91.65%-46.72%

Vaxcyte has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

In the previous week, Vaxcyte had 8 more articles in the media than Arcus Biosciences. MarketBeat recorded 11 mentions for Vaxcyte and 3 mentions for Arcus Biosciences. Vaxcyte's average media sentiment score of 0.88 beat Arcus Biosciences' score of 0.26 indicating that Vaxcyte is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vaxcyte
4 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Arcus Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Arcus Biosciences beats Vaxcyte on 8 of the 15 factors compared between the two stocks.

How does Arcus Biosciences compare to ImmunityBio?

Arcus Biosciences (NYSE:RCUS) and ImmunityBio (NASDAQ:IBRX) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Arcus Biosciences has a net margin of -453.00% compared to ImmunityBio's net margin of -607.79%. ImmunityBio's return on equity of 0.00% beat Arcus Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcus Biosciences-453.00% -91.65% -46.72%
ImmunityBio -607.79%N/A -54.83%

In the previous week, ImmunityBio had 22 more articles in the media than Arcus Biosciences. MarketBeat recorded 25 mentions for ImmunityBio and 3 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 0.26 beat ImmunityBio's score of -0.17 indicating that Arcus Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcus Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
ImmunityBio
2 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Arcus Biosciences has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market.

Arcus Biosciences currently has a consensus price target of $39.36, indicating a potential upside of 133.63%. ImmunityBio has a consensus price target of $16.00, indicating a potential upside of 167.56%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts clearly believe ImmunityBio is more favorable than Arcus Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcus Biosciences
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.69
ImmunityBio
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 7.6% of Arcus Biosciences shares are held by company insiders. Comparatively, 66.1% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ImmunityBio has lower revenue, but higher earnings than Arcus Biosciences. ImmunityBio is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcus Biosciences$247M9.82-$353M-$3.63N/A
ImmunityBio$113.29M56.15-$351.40M-$1.08N/A

Summary

Arcus Biosciences and ImmunityBio tied by winning 8 of the 16 factors compared between the two stocks.

How does Arcus Biosciences compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Arcus Biosciences (NYSE:RCUS) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

TG Therapeutics has a net margin of 11.81% compared to Arcus Biosciences' net margin of -453.00%. TG Therapeutics' return on equity of 18.82% beat Arcus Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
TG Therapeutics11.81% 18.82% 7.78%
Arcus Biosciences -453.00%-91.65%-46.72%

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by company insiders. Comparatively, 7.6% of Arcus Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, TG Therapeutics had 13 more articles in the media than Arcus Biosciences. MarketBeat recorded 16 mentions for TG Therapeutics and 3 mentions for Arcus Biosciences. TG Therapeutics' average media sentiment score of 0.44 beat Arcus Biosciences' score of 0.26 indicating that TG Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TG Therapeutics
5 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arcus Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

TG Therapeutics has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TG Therapeutics$616.29M15.39$447.18M$0.6695.09
Arcus Biosciences$247M9.82-$353M-$3.63N/A

TG Therapeutics currently has a consensus target price of $63.00, suggesting a potential upside of 0.38%. Arcus Biosciences has a consensus target price of $39.36, suggesting a potential upside of 133.63%. Given Arcus Biosciences' higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than TG Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TG Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Arcus Biosciences
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.69

TG Therapeutics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Summary

TG Therapeutics beats Arcus Biosciences on 14 of the 17 factors compared between the two stocks.

How does Arcus Biosciences compare to Spyre Therapeutics?

Arcus Biosciences (NYSE:RCUS) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Arcus Biosciences currently has a consensus target price of $39.36, suggesting a potential upside of 133.63%. Spyre Therapeutics has a consensus target price of $110.53, suggesting a potential upside of 11.23%. Given Arcus Biosciences' higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than Spyre Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcus Biosciences
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.69
Spyre Therapeutics
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
2.94

Arcus Biosciences has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.24, indicating that its stock price is 224% more volatile than the broader market.

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 7.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Spyre Therapeutics has lower revenue, but higher earnings than Arcus Biosciences. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcus Biosciences$247M9.82-$353M-$3.63N/A
Spyre Therapeutics$890K10,603.56-$155.20M-$2.74N/A

Spyre Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -453.00%. Spyre Therapeutics' return on equity of -35.97% beat Arcus Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcus Biosciences-453.00% -91.65% -46.72%
Spyre Therapeutics N/A -35.97%-27.67%

In the previous week, Arcus Biosciences and Arcus Biosciences both had 3 articles in the media. Spyre Therapeutics' average media sentiment score of 0.56 beat Arcus Biosciences' score of 0.26 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcus Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Spyre Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Spyre Therapeutics beats Arcus Biosciences on 12 of the 16 factors compared between the two stocks.

How does Arcus Biosciences compare to Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Arcus Biosciences (NYSE:RCUS) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Madrigal Pharmaceuticals presently has a consensus price target of $706.87, suggesting a potential upside of 66.73%. Arcus Biosciences has a consensus price target of $39.36, suggesting a potential upside of 133.63%. Given Arcus Biosciences' higher probable upside, analysts plainly believe Arcus Biosciences is more favorable than Madrigal Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Madrigal Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.76
Arcus Biosciences
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.69

Madrigal Pharmaceuticals has a net margin of -10.89% compared to Arcus Biosciences' net margin of -453.00%. Madrigal Pharmaceuticals' return on equity of -27.08% beat Arcus Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Madrigal Pharmaceuticals-10.89% -27.08% -12.04%
Arcus Biosciences -453.00%-91.65%-46.72%

In the previous week, Madrigal Pharmaceuticals had 8 more articles in the media than Arcus Biosciences. MarketBeat recorded 11 mentions for Madrigal Pharmaceuticals and 3 mentions for Arcus Biosciences. Madrigal Pharmaceuticals' average media sentiment score of 0.28 beat Arcus Biosciences' score of 0.26 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Madrigal Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arcus Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Madrigal Pharmaceuticals has higher revenue and earnings than Arcus Biosciences. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Madrigal Pharmaceuticals$958.40M10.28-$288.28M-$5.98N/A
Arcus Biosciences$247M9.82-$353M-$3.63N/A

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 7.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Madrigal Pharmaceuticals has a beta of -0.98, indicating that its stock price is 198% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market.

Summary

Madrigal Pharmaceuticals beats Arcus Biosciences on 12 of the 15 factors compared between the two stocks.

Get Arcus Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RCUS vs. The Competition

MetricArcus BiosciencesBiotechnology IndustryHealthcare SectorNYSE Exchange
Market Cap$2.56B$4.15B$7.83B$23.49B
Dividend YieldN/A3.62%2.46%3.79%
P/E Ratio-4.6426.5433.3824.92
Price / Sales9.8216.048.593.24
Price / CashN/A26.3721.9315.51
Price / Book6.774.074.403.66
Net Income-$353M-$22.86M$3.52B$1.08B
7 Day Performance-9.72%-6.15%-4.48%-2.50%
1 Month Performance-23.64%-4.92%-3.53%-1.20%
1 Year Performance-15.68%-3.09%0.12%7.34%

Arcus Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RCUS
Arcus Biosciences
2.9192 of 5 stars
$16.85
-3.3%
$39.36
+133.6%
-16.1%$2.56B$247MN/A601
PCVX
Vaxcyte
3.0542 of 5 stars
$67.53
+5.7%
$110.50
+63.6%
+26.5%$9.77BN/AN/A507
IBRX
ImmunityBio
1.754 of 5 stars
$7.11
-17.7%
$16.00
+125.0%
+187.5%$9.46B$113.29MN/A691
TGTX
TG Therapeutics
1.7903 of 5 stars
$63.38
+5.9%
$63.00
-0.6%
+102.5%$9.43B$616.29M23.13399
SYRE
Spyre Therapeutics
2.044 of 5 stars
$109.00
+4.9%
$110.53
+1.4%
+322.9%$9.41B$890KN/A130

Related Companies and Tools


This page (NYSE:RCUS) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners